文献速递白血病造血干细胞移植与细胞治疗

贝林妥欧单抗治疗成人B细胞前体急性淋巴细胞白血病微小残留病

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
PubMed 文献 · Blood · 2018-01-22

这项开放标签单臂研究纳入116例经多药治疗后达血液学完全缓解但微小残留病(MRD)≥10⁻³的成人B细胞前体急性淋巴细胞白血病患者,接受贝林妥欧单抗15 µg/m²/日持续静脉输注最多4个周期。113例可评估患者中88例(78%)获得完全MRD缓解;完全MRD缓解者较未缓解者无复发生存(23.6 vs 5.7个月,P=.002)和总生存(38.9 vs 12.5个月,P=.002)更长。

要点

  • 113例可评估患者中88例(78%)在1个周期后获得完全MRD缓解。
  • 完全MRD缓解者无复发生存23.6个月 vs 未缓解者5.7个月(P=.002)。
  • 完全MRD缓解者总生存38.9个月 vs 未缓解者12.5个月(P=.002)。

核心结论

  • 在MRD阳性B细胞前体急性淋巴细胞白血病患者中,贝林妥欧单抗治疗后多数获得完全MRD缓解,且与MRD未缓解者相比无复发生存和总生存显著更长。

研究设计与样本

  • 开放标签、单臂研究,纳入116例经多药治疗后达血液学完全缓解且MRD≥10⁻³的成人B细胞前体急性淋巴细胞白血病患者。
  • 贝林妥欧单抗15 µg/m²/日持续静脉输注,最多4个周期;第1周期后可随时接受异基因造血干细胞移植。
  • 主要终点为贝林妥欧单抗1个周期后的完全MRD缓解状态;研究注册号NCT01207388。

主要发现

  • 113例可评估患者中88例(78%)获得完全MRD缓解。
  • 110例Ph阴性且血液学缓解患者中,18个月无复发生存率的Kaplan-Meier估计为54%,中位总生存为36.5个月。
  • 里程碑分析中,完全MRD缓解者无复发生存23.6个月 vs MRD未缓解者5.7个月(P=.002)。
  • 里程碑分析中,完全MRD缓解者总生存38.9个月 vs MRD未缓解者12.5个月(P=.002)。
  • 不良事件与既往贝林妥欧单抗研究一致;12例(10%)发生3级神经系统事件,3例(3%)发生4级神经系统事件;4例(3%)发生细胞因子释放综合征(1级2例,3级2例),均发生于第1周期。

关键数值与推荐

  • MRD阳性定义为≥10⁻³。
  • 贝林妥欧单抗剂量为15 µg/m²/日持续静脉输注,最多4个周期。
  • 主要终点为1个周期后的完全MRD缓解状态。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL. In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete remission with MRD (≥10-3) received blinatumomab 15 µg/m2 per day by continuous IV infusion for up to 4 cycles. Patients could undergo allogeneic hematopoietic stem-cell transplantation any time after cycle 1. The primary end point was complete MRD response status after 1 cycle of blinatumomab. One hundred sixteen patients received blinatumomab. Eighty-eight (78%) of 113 evaluable patients achieved a complete MRD response. In the subgroup of 110 patients with Ph-negative ALL in hematologic remission, the Kaplan-Meier estimate of relapse-free survival (RFS) at 18 months was 54%. Median overall survival (OS) was 36.5 months. In landmark analyses, complete MRD responders had longer RFS (23.6 vs 5.7 months; P = .002) and OS (38.9 vs 12.5 months; P = .002) compared with MRD nonresponders. Adverse events were consistent with previous studies of blinatumomab. Twelve (10%) and 3 patients (3%) had grade 3 or 4 neurologic events, respectively. Four patients (3%) had cytokine release syndrome grade 1, n = 2; grade 3, n = 2), all during cycle 1. After treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, a majority achieved a complete MRD response, which was associated with significantly longer RFS and OS compared with MRD nonresponders. This study is registered at www.clinicaltrials.gov as #NCT01207388.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018. PMID: 29358182. doi:10.1182/blood-2017-08-798322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。